← Back to patent-cliff list
DH-001
Tier C — Watch / tradeDH-001
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Solid tumour, Cardiomyopathy, Arrhythmia, Heart failure, 心脏毒性作用, 药物中毒
Regional status
US
-
EU
-
China
Phase II
2023-04-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DH-001?
Approved indications include: Solid tumour, Cardiomyopathy, Arrhythmia, Heart failure, 心脏毒性作用, 药物中毒.
When does the DH-001 patent expire?
No public expiry year is available for DH-001 yet; this page updates once verified.
How do I get a quote for DH-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03